Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| HYPD | 8-K | bullish | 7/10 | Hyperion DeFi reported Q2 2026 GAAP net income of $31.0M, a second consecutive record, driven by $54.8M in non-GAAP trea | Aug 12, 2026 |
| DERM | PRESS-RELEASE | bearish | 6/10 | Journey Medical reported Q1 2026 EPS of -$0.08, a 255.6% miss vs consensus of -$0.02, with revenue of $18.5M slightly ab | Aug 12, 2026 |
| OTLK | 8-K | bearish | 7/10 | Outlook Therapeutics filed an 8-K reporting preliminary cash of ~$11.2M as of June 30, 2026, confirming a going-concern | Aug 12, 2026 |
| MRK | ANALYST-UPGRADE | bullish | 4/10 | Daiwa Capital double-upgraded Merck & Co. (MRK) from Neutral to Outperform on August 12, 2026, raising its price target | Aug 12, 2026 |
| ONCO | S-1 | bearish | 8/10 | Onconetix filed an S-1 registration statement to register the resale of up to 100,000,000 shares of common stock by Seve | Aug 12, 2026 |
| AGEN | INST-CLUSTER | mixed | 4/10 | Five institutional investors, led by BlackRock and Geode, doubled their AGEN positions in Q2 2026, adding a net $8.9M to | Aug 12, 2026 |
| ACTU | INST-CLUSTER | bearish | 4/10 | A mixed institutional cluster for ACTU shows two small asset managers doubling tiny positions (total buying ~$4K) while | Aug 12, 2026 |
| AARD | INST-CLUSTER | bearish | 6/10 | Aardvark Therapeutics Q2 2026 13F cluster reveals a stark divergence: three small asset managers doubled their tiny posi | Aug 12, 2026 |
| ABOS | INST-CLUSTER | neutral | 4/10 | Four major institutional investors, led by BlackRock and Geode, more than doubled their ABOS positions in Q2 2026, addin | Aug 12, 2026 |
| PHVS | 6-K | neutral | 6/10 | Pharvaris reported Q2 2026 financial results with no revenue, a net loss of €47.8M (€0.70/share), and cash of €318M. The | Aug 12, 2026 |
| ABOS | 8-K | neutral | 5/10 | Acumen Pharmaceuticals reported Q2 2026 EPS of -$0.45, missing the consensus estimate of -$0.41 by 11%. As a pre-revenue | Aug 12, 2026 |
| ZLAB | 144 | neutral | 2/10 | Director William Lis filed a Form 144 to sell 8,506 American Depositary Shares (ADS) valued at approximately $212,650, a | Aug 12, 2026 |
| LXEO | 8-K | bullish | 7/10 | Lexeo Therapeutics reported Q2 2026 financial results with a net loss of $0.30 per share, slightly better than the $0.30 | Aug 12, 2026 |
| CANF | 6-K | neutral | 3/10 | Can-Fite BioPharma issued a press release on August 12, 2026, highlighting the advanced FDA and EMA regulatory status of | Aug 12, 2026 |
| HUMA | 8-K | mixed | 6/10 | Humacyte reported Q2 2026 results with product revenue of $0.4M (up from $0.1M YoY) but a net loss of $36.8M, missing co | Aug 12, 2026 |
| KMDA | 6-K | bullish | 6/10 | Kamada reported record-high Q2 and H1 2026 results with double-digit revenue and profit growth, driven by strong demand | Aug 12, 2026 |
| CYPH | 8-K | mixed | 6/10 | Cypherpunk Technologies reported Q2 2026 net income of $39.4M ($0.18 diluted), swinging from a $16.6M net loss in Q2 202 | Aug 12, 2026 |
| TCRX | 8-K | bearish | 6/10 | TScan Therapeutics reported Q2 2026 results with revenue of $1.1M (down 66% YoY from $3.1M) and a net loss of $30.4M ($- | Aug 12, 2026 |
| STRO | 8-K | bullish | 7/10 | Sutro Biopharma reported Q2 2026 revenue of $9.8M (vs $63.7M YoY) and a net loss of $38.5M (EPS -$2.33 vs -$1.35 YoY), a | Aug 12, 2026 |
| SAFX | 8-K | bullish | 5/10 | XCF Global (SAFX) announced initial renewable diesel sales to Tartan Oil LLC, a Berkshire Hathaway subsidiary, from its | Aug 12, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab A/S filed its updated Articles of Association on August 11, 2026, via a Form 6-K on August 12, 2026. The filing i | Aug 12, 2026 |
| MNPR | PRESS-RELEASE | bullish | 6/10 | Monopar Therapeutics reported a Q2 2026 net loss of $5.3M ($0.62/share), wider than the $2.5M loss in Q2 2025, driven by | Aug 12, 2026 |
| MNPR | 8-K | bullish | 6/10 | Monopar Therapeutics reported Q2 2026 net loss of $5.3M ($0.62/share), wider than the $2.5M loss in Q2 2025, driven by i | Aug 12, 2026 |
| DFTX | 8-K | bullish | 7/10 | Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120 ODT in generalized anxie | Aug 12, 2026 |
| LTGO | 3 | bullish | 7/10 | Sanofi filed a Form 3 initial statement of beneficial ownership for Latigo Biotherapeutics (LTGO), disclosing a signific | Aug 12, 2026 |
| SPRB | 8-K | neutral | 6/10 | Spruce Biosciences reported Q2 2026 net loss of $16.2M ($6.68/share) vs $2.1M loss ($3.50/share) in Q2 2025, with no rev | Aug 12, 2026 |
| SPRC | 6-K | neutral | 4/10 | SciSparc's majority-owned subsidiary NeuroThera Labs was granted a Japanese patent for a proprietary combination of 4-am | Aug 12, 2026 |
| MDGL | 8-K | neutral | 3/10 | Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., a top R&D executive from Johnson & Johnson, to its Board o | Aug 12, 2026 |
| CTOR | 8-K | neutral | 2/10 | Citius Oncology appointed Jonathan Peri, Ph.D., J.D., as an independent Class I director, expanding the board to nine me | Aug 12, 2026 |
| NTHI | 8-K | bullish | 7/10 | NeOnc Technologies reported positive Phase 2a topline results for intranasal NEO100 in recurrent IDH1-mutant high-grade | Aug 12, 2026 |